Improve primary data collection within Scope greenhouse gas accounting to cover vast majority of impacts by 2020 Waste 10% absolute reduction against a 2015 baseline Resource efficiency 90% of small molecule active pharmaceutical ingredients (API) syntheses meet resource efficiency targets at launch Establish equivalent resource efficiency targets for biologics (drugs that are manufactured in a living system, such as plant or animal cells, as opposed to chemical synthesis) Water Maintain usage at 2015 level as our business grows Ensure effective environmental management of our products from pre-launch through to product end-of-life 1 Extended operational footprint includes: Scope 1, Scope 2 and some material Scope 3 emissions.